Kolon Life Science to Attend CPHI 2026...Expanding API and CDMO Businesses
Introduction of New API Items such as Phosphoramidite
Showcasing CDMO Capabilities in Process Development, Production, and Regulatory Compliance
Kolon Life Science announced on September 8 that it will participate with its own booth at 'CPHI Worldwide 2026', a global pharmaceutical industry exhibition to be held in Milan, Italy, from October 6 to 8 next month.
Aerial view of Kolon Life Science's booth at "CPHI Worldwide 2026." Kolon Life Science
View original imageAt this exhibition, Kolon Life Science plans to showcase its existing Active Pharmaceutical Ingredient (API) business as well as new supply items, and present its Contract Development and Manufacturing Organization (CDMO) services, which cover the entire process from research and development to production and regulatory compliance.
The company supplies APIs such as anti-inflammatory and analgesic agents and hyperlipidemia treatments to global markets, including Japan. It has undergone quality audits by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and local pharmaceutical companies, and has strengthened its quality management system by obtaining Good Manufacturing Practice (GMP) certification from Brazil's National Health Surveillance Agency (ANVISA).
As a new API product, Kolon Life Science will introduce phosphoramidite, which is used in RNA therapeutics. The company plans to present basic phosphoramidites for DNA and RNA, a variety of modified products, and customer-tailored development solutions.
For the CDMO division, the company will introduce its business capabilities focused on customer-specific Chemistry, Manufacturing, and Controls (CMC) services, supporting processes ranging from process development to production and regulatory submissions. Based on its accumulated production and quality management expertise in the API business, the company plans to provide support from process design at the early development stage to commercial production.
Hot Picks Today
"Why Is the Amount in My Account So Low?"... Why Pension Savings Subscribers Were Surprised
- "After Sleeping Well with Strangers"... Who Is the 24-Year-Old Woman Who Won 19 Million Won?
- "SK hynix to Hit 4.7 Million Won, Samsung 670,000 Won"... Why Nomura's Bold Forecast justifies it
- "Even Underwear Has to Be Cut Up with Scissors"... China Hit by Rise of "Trash Hunters" in an "If You're Slow, You're Out" Scramble
- "NPS loses 240 trillion won, 1990s-born get zero pension"... What's behind rumors spreading after the KOSPI plunge?
Lee Hanguk, CEO of Kolon Life Science, said, "CPHI Worldwide 2026 will be an opportunity for Kolon Life Science to showcase its accumulated business competitiveness and broad portfolio to global clients. We will actively demonstrate our capabilities to respond to the diverse needs of our customers with customized solutions."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
